Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Feasibility study for collection of HER2 data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program central cancer registries.

Reichman ME, Altekruse S, Li CI, Chen VW, Deapen D, Potts M, Wu XC, Morrell D, Hafterson J, Phipps AI, Harlan LC, Ries LG, Edwards BK.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):144-7. doi: 10.1158/1055-9965.EPI-09-0807.

2.

CerbB2 status in breast cancer: pathologic issues.

Lian SC, Tan PH.

Ann Acad Med Singapore. 2002 Nov;31(6):793-8. Review.

PMID:
12520836
3.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force.

J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.

PMID:
16813731
4.

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis.

Dendukuri N, Khetani K, McIsaac M, Brophy J.

CMAJ. 2007 May 8;176(10):1429-34. Review.

5.

Emerging technologies for assessing HER2 amplification.

Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M.

Am J Clin Pathol. 2009 Oct;132(4):539-48. doi: 10.1309/AJCPV2I0HGPMGBSQ. Review.

PMID:
19762531
6.

Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).

Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M, Hasegawa T, Osamura RY.

Breast Cancer. 2001;8(4):316-20. Review.

PMID:
11791124
7.

Current use of HER2 tests.

Schaller G, Evers K, Papadopoulos S, Ebert A, Bühler H.

Ann Oncol. 2001;12 Suppl 1:S97-100. Review.

PMID:
11521731
8.

The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship.

Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME.

Am J Surg Pathol. 2016 Dec;40(12):e94-e102. Review.

PMID:
27740970
9.

SEER cancer registry biospecimen research: yesterday and tomorrow.

Altekruse SF, Rosenfeld GE, Carrick DM, Pressman EJ, Schully SD, Mechanic LE, Cronin KA, Hernandez BY, Lynch CF, Cozen W, Khoury MJ, Penberthy LT.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2681-7. doi: 10.1158/1055-9965.EPI-14-0490. Review.

Supplemental Content

Support Center